Dutch pension fund dumps Mylan on worries about death penalty drug

Europeans have had a bone to pick with companies supplying death penalty drugs to U.S. prisons, with government officials restricting exports and prompting shortages. In the latest chapter of the saga, a Dutch pension fund is selling out of Mylan ($MYL) after discovering that one of its products is stocked at a U.S. prison that carries out executions. More from FiercePharma

Suggested Articles

After showing Nucala could cut the rates of flares for hypereosinophilic syndrome, GSK is planning regulatory filings in 2020.

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Both IL-17A inhibitors have rolled out data showing they work in non-radiographic axial spondyloarthritis.